MGT-1143

MGT-1143 is a novel antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17), a calcium-dependent adhesion molecule that is frequently overexpressed in various gastrointestinal malignancies and associated with poor prognosis. Developed by Marigold, the agent comprises a fully humanized anti-CDH17 monoclonal antibody conjugated to an exatecan-based cytotoxic payload via a proprietary linker platform. MGT-1143 is designed to selectively bind to CDH17 on the surface of tumor cells, undergo rapid internalization, and release the exatecan payload, which acts as a topoisomerase I inhibitor to induce DNA damage and apoptosis. Preclinical evaluations have demonstrated high target specificity, potent cytotoxicity across multiple CDH17-positive cell lines, and robust, dose-dependent anti-tumor activity in xenograft models of gastrointestinal cancers, including esophageal, gastric, pancreatic, and colorectal cancers.